| Roy Marie A Margallo, MD | |
|
10624 S Eastern Ave Ste A-955, Henderson, NV 89052-2982 | |
| (702) 380-1888 | |
| (702) 463-1507 |
| Full Name | Roy Marie A Margallo |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 30 Years |
| Location | 10624 S Eastern Ave Ste A-955, Henderson, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538314950 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 14033 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Encompass Health Home Health | Las vegas, NV | Home health agency |
| Advanced Home Care | Henderson, NV | Home health agency |
| Desert Grace Home Health | Las vegas, NV | Home health agency |
| Summerlin Hospital Medical Center | Las vegas, NV | Hospital |
| Henderson Hospital | Henderson, NV | Hospital |
| Advanced Health Care Of Las Vegas | Las vegas, NV | Nursing home |
| Advanced Health Care Of Henderson | Las vegas, NV | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Quality Medical Specialists Llc | 1759705932 | 2 |
News Archive
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
Information technology and electronics are becoming entwined with our everyday lives in industry, the service sector, transport, logistics, health care, housing, education, and our leisure time, almost without our noticing it.
"The big three" infections AIDS, TB and malaria have caught the world's attention but other disabling and fatal infectious diseases in Africa are being ignored, say three eminent tropical disease researchers in the international health journal PLoS Medicine.
The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only shown modest clinical activity with patients who receive these drugs experiencing very little improvement in survival.
› Verified 2 days ago
| Entity Name | Platinum Hospitalists Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861627242 PECOS PAC ID: 7214076322 Enrollment ID: O20091203000160 |
News Archive
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
Information technology and electronics are becoming entwined with our everyday lives in industry, the service sector, transport, logistics, health care, housing, education, and our leisure time, almost without our noticing it.
"The big three" infections AIDS, TB and malaria have caught the world's attention but other disabling and fatal infectious diseases in Africa are being ignored, say three eminent tropical disease researchers in the international health journal PLoS Medicine.
The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only shown modest clinical activity with patients who receive these drugs experiencing very little improvement in survival.
› Verified 2 days ago
| Entity Name | Quality Medical Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154948024 PECOS PAC ID: 1759705932 Enrollment ID: O20200721002422 |
News Archive
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
Information technology and electronics are becoming entwined with our everyday lives in industry, the service sector, transport, logistics, health care, housing, education, and our leisure time, almost without our noticing it.
"The big three" infections AIDS, TB and malaria have caught the world's attention but other disabling and fatal infectious diseases in Africa are being ignored, say three eminent tropical disease researchers in the international health journal PLoS Medicine.
The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only shown modest clinical activity with patients who receive these drugs experiencing very little improvement in survival.
› Verified 2 days ago
| Entity Name | Celestial Health Solutions |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124731401 PECOS PAC ID: 8527439603 Enrollment ID: O20230127002203 |
News Archive
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
Information technology and electronics are becoming entwined with our everyday lives in industry, the service sector, transport, logistics, health care, housing, education, and our leisure time, almost without our noticing it.
"The big three" infections AIDS, TB and malaria have caught the world's attention but other disabling and fatal infectious diseases in Africa are being ignored, say three eminent tropical disease researchers in the international health journal PLoS Medicine.
The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only shown modest clinical activity with patients who receive these drugs experiencing very little improvement in survival.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Roy Marie A Margallo, MD 10624 S Eastern Ave Ste A-955, Henderson, NV 89052-2982 Ph: (702) 380-1888 | Roy Marie A Margallo, MD 10624 S Eastern Ave Ste A-955, Henderson, NV 89052-2982 Ph: (702) 380-1888 |
News Archive
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
Information technology and electronics are becoming entwined with our everyday lives in industry, the service sector, transport, logistics, health care, housing, education, and our leisure time, almost without our noticing it.
"The big three" infections AIDS, TB and malaria have caught the world's attention but other disabling and fatal infectious diseases in Africa are being ignored, say three eminent tropical disease researchers in the international health journal PLoS Medicine.
The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only shown modest clinical activity with patients who receive these drugs experiencing very little improvement in survival.
› Verified 2 days ago
James B Gabroy, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1535 West Warm Spring Road, Suite 135, Henderson, NV 89014 Phone: 702-450-3385 Fax: 702-898-1699 | |
Dr. Poupak Ziaei, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2641 W Horizon Ridge Pkwy Ste 100, Henderson, NV 89052 Phone: 702-616-0091 Fax: 702-616-2329 | |
Dr. Jeannette Nee, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2865 Siena Heights Dr, Suite 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 | |
Wen Liang, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2621 W Horizon Ridge Pkwy, Suite 150, Henderson, NV 89052 Phone: 702-837-6368 Fax: 702-837-0685 | |
Randy James Ip, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2865 Siena Heights Dr Ste 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 | |
Linda Lou Johnson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 W Sunset Rd, Henderson, NV 89014 Phone: 725-269-7001 Fax: 725-269-7003 | |
Dr. Daejoon Anh, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2865 Siena Heights Dr Ste 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 |